LUC7L2

Across TCGA pan-cancer cohorts, LUC7L2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LUC7L2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher LUC7L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LUC7L2 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

COAD, PDAC, and HNSC are the cancer types where LUC7L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	III,IV	1.000	0.724	.029	36	view →
PDAC	DFS	Median	III,IV	0.980	0.435	<.001	21	view →
HNSC	DFS	Tertile	IV	0.776	1.000	.024	11	view →
UCEC	DFS	Tertile	II,III,IV	0.904	0.466	.021	8	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	4	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →
GBM	OS	Quartile	All	0.670	0.968	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LUC7L2–COAD (DFS)

Open the COAD breakdown →